It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
To what extent and how post-transcriptional dysregulation affects aging proteome remains unclear. Here, we provide proteomic data of whole-tissue lysates (WTL) and low-solubility protein-enriched fractions (LSF) of major tissues collected from mice of 6, 15, 24, and 30 months of age. Low-solubility proteins are preferentially affected by age and the analysis of LSF doubles the number of proteins identified to be differentially expressed with age. Simultaneous analysis of proteome and transcriptome using the same tissue homogenates reveals the features of age-related post-transcriptional dysregulation. Post-transcriptional dysregulation becomes evident especially after 24 months of age and age-related post-transcriptional dysregulation leads to accumulation of core matrisome proteins and reduction of mitochondrial membrane proteins in multiple tissues. Based on our in-depth proteomic data and sample-matched transcriptome data of adult, middle-aged, old, and geriatric mice, we construct the Mouse aging proteomic atlas (https://aging-proteomics.info/), which provides a thorough and integrative view of age-related gene expression changes.
Comprehensive investigation of proteome changes in old-age across mammalian tissues was missing. Here, the authors provide proteome and transcriptome data of major tissues of 6, 15, 24, and 30-month-old mice. Age-related post-transcriptional dysregulation most affects ECM and OXPHOS proteins.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Graduate School of Medicine, Department of Pathophysiology, Osaka Metropolitan University, Osaka, Japan
2 EMBL Heidelberg, Proteomic Core Facility, Heidelberg, Germany (GRID:grid.4709.a) (ISNI:0000 0004 0495 846X)
3 Health and Nutrition, Laboratory of Proteomics for Drug Discovery, Center for Drug Design Research, National Institute of Biomedical Innovation, Osaka, Japan (GRID:grid.482562.f)
4 Kyoto University, Medical Research Support Center, Graduate School of Medicine, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)
5 University of Rochester, Department of Biology, Rochester, USA (GRID:grid.16416.34) (ISNI:0000 0004 1936 9174)
6 Graduate School of Medicine, Department of Pathophysiology, Osaka Metropolitan University, Osaka, Japan (GRID:grid.16416.34)